Author

J. M. Jimenez-Guardeno

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

M. H. Malim· 2 shared A. C. Hayday· 1 shared A. G. Laing· 1 shared A. M. Ortega-Prieto· 1 shared A. Mercadal Playa· 1 shared A. Richardson· 1 shared A. Rosa· 1 shared B. Menendez Moreno· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

M. H. Malim

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MicrobiologybioRxivPreprintJun 25, 2021

Drug repurposing based on a Quantum-Inspired method versus classical fingerprinting uncovers potential antivirals against SARS-CoV-2 including vitamin B12

J. M. Jimenez-Guardeno, A. M. Ortega-Prieto, B. Menendez Moreno…·R. T. Martinez-Nunez

This paper compares a quantum-inspired method and traditional fingerprinting to repurpose drugs against SARS-CoV-2, identifying vitamin B12 and BMS-986094 as potential antivirals effective against multiple variants.

DOI 10.1101/2021.06.25.449609

humanbulk RNA-seq

𝕏 PostBluesky

ImmunologybioRxivPreprintFeb 3, 2021

Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike

C. Graham, J. Seow, I. Huettner…·K. J. Doores

This study examines how mutations in the B.1.1.7 variant of SARS-CoV-2 affect neutralization by monoclonal antibodies targeting non-RBD epitopes.

DOI 10.1101/2021.02.03.429355

humanproteomics

𝕏 PostBluesky